ArticleFrontiers in medicine2025
Immunoglobulin levels of children with bronchiolitis obliterans syndrome after hematopoietic cell transplantation.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of busulfan exposure stratification on transplant outcomes and immune reconstitution in children with severe aplastic anemia.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The development of bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic stem cell transplantation (allo-HCT) remains an unresolved clinical problem. However, developing a risk stratification tool for BOS risk is challenging as numerous factors contribute to its development. Moreover, allo-HCT may lead to a decrease in respiratory mucosal surface defense function, resulting in recurrent inflammation and fibrosis. Previous studies have shown that immunoglobulin G (IgG) and IgA levels significantly decrease after lung transplantation and are associated with BOS. Therefore, we hypothesized that immunoglobulin levels of patients may also decrease after allo-HCT, and may even be risk factor for the development of BOS. Methods: In this retrospective study, a total of 134 patients were enrolled. According to the presence of BOS, these patients were divided into BOS and non-BOS groups. Clinical information and immunoglobulin levels were analyzed between the two groups. Immunoglobulin levels of patients before and after transplantation were compared. Binary logistic regression and Cox regression were used to identify variables with independent prognostic significance. Results: ABO incompatible, human leukocyte antigen (HLA) mismatch, lung infection within 100 days post-transplantation, cytomegalovirus (CMV) serology positivity, and pre-transplant IgA immunoglobulin deficiency were risk factors for BOS after allo-HCT. Following transplantation, IgA and IgM levels significantly decreased, and many patients had levels below the reference values. In addition, the serum IgA levels prior to transplantation were lower in the BOS group than the non-BOS group. In multivariate models, pre-transplant IgA deficiency was a risk factor for BOS. Conclusion: Following allo-HCT, IgA and IgM levels decreased, and numerous patients had levels below the reference values. In multivariate models, pre-transplant IgA deficiency was identified as a risk factor for BOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.